MBX Biosciences (NASDAQ:MBX) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Unusually-high trading volume: About 865,252 shares traded (a 37% increase from the prior session) with the stock last at $30.4950 after a prior close of $31.30, and the article notes the share price was down ~5.9%.
• Analyst sentiment: Ratings are mixed but skew positive — MarketBeat shows an average rating of "Moderate Buy" with a consensus price target of $51.56 (1 Strong Buy, 10 Buy, 2 Sell among analysts).
• Insider buy and recent results: CEO P. Kent Hawryluk purchased 18,500 shares at $28.41 and insiders collectively own 52.19% of shares; the company reported Q most recent EPS of ($0.49), beating the ($0.64) consensus by $0.15.

Shares of MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 865,252 shares changed hands during mid-day trading, an increase of 37% from the previous session's volume of 631,091 shares.The stock last traded at $30.4950 and had previously closed at $31.30.

Wall Street Analysts Forecast Growth

MBX has been the subject of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of MBX Biosciences in a report on Thursday, January 22nd. Lifesci Capital upgraded shares of MBX Biosciences to a "strong-buy" rating in a report on Tuesday, March 31st. Barclays began coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an "overweight" rating and a $66.00 price target on the stock. Wall Street Zen raised shares of MBX Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, December 21st. Finally, TD Cowen reaffirmed a "buy" rating on shares of MBX Biosciences in a report on Thursday, March 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $51.56.

MBX Biosciences Stock Down 5.9%

The company's 50 day moving average price is $33.20 and its 200 day moving average price is $28.68. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -12.38 and a beta of 1.25.

MBX Biosciences (NASDAQ:MBX - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.15.

Insider Activity at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk bought 18,500 shares of the firm's stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the completion of the transaction, the chief executive officer directly owned 486,777 shares of the company's stock, valued at approximately $13,829,334.57. This trade represents a 3.95% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 52.19% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP acquired a new position in MBX Biosciences during the third quarter valued at $1,488,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in MBX Biosciences during the third quarter valued at $498,000. Resolute Capital Asset Partners LLC acquired a new position in MBX Biosciences during the second quarter valued at $567,000. Walleye Capital LLC lifted its position in MBX Biosciences by 116.5% during the second quarter. Walleye Capital LLC now owns 70,333 shares of the company's stock valued at $802,000 after purchasing an additional 37,843 shares during the period. Finally, Baker BROS. Advisors LP acquired a new position in MBX Biosciences during the third quarter valued at $4,861,000.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.